Topiramate is a sulfamate-substituted monosaccharide anticonvulsant and neuromodulator. It is a second-generation antiepileptic drug (AED) with multiple mechanisms of action, used primarily for epilepsy and migraine prophylaxis. In the Indian context, it is widely prescribed due to its broad-spectrum efficacy and favorable pharmacokinetic profile, though it requires careful titration to manage CNS-related side effects.
Adult: Epilepsy (Adjunctive): Initiate at 25-50 mg/day, titrate by 25-50 mg/week to effective dose of 200-400 mg/day in two divided doses. Migraine Prophylaxis: Initiate at 25 mg/day, titrate to 100 mg/day in two divided doses (50 mg BID).
Note: Tablets should be swallowed whole with water, without chewing or crushing. Can be taken with or without food. Maintain adequate fluid intake to reduce risk of kidney stones. For patients unable to swallow tablets, sprinkle capsules are available from some brands.
Topiramate exhibits a unique and multifaceted mechanism of action, contributing to its broad-spectrum efficacy. It modulates neuronal excitability through: 1) State-dependent blockade of voltage-gated sodium channels, 2) Potentiation of GABA-A receptor-mediated inhibitory neurotransmission, 3) Antagonism of AMPA/kainate subtypes of glutamate receptors, 4) Inhibition of high-voltage-activated calcium channels (L-type), and 5) Weak inhibition of carbonic anhydrase isoenzymes CA-II and CA-IV.
Pregnancy: Pregnancy Category D (US FDA). Data from pregnancy registries indicate an increased risk of major congenital malformations (e.g., cleft lip/palate, hypospadias) with topiramate monotherapy. Risk is dose-dependent. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Folic acid supplementation (5 mg/day) is recommended before and during pregnancy. In India, strict contraception is advised for women of childbearing potential.
Driving: May impair ability to drive or operate machinery. Patients should not drive until they know how topiramate affects them, especially during dose titration. Effects include dizziness, fatigue, blurred vision, and cognitive slowing.
| Phenytoin | Decreases topiramate plasma levels by ~48% due to enzyme induction. May require topiramate dose adjustment. | Major |
| Carbamazepine | Decreases topiramate plasma levels by ~40% due to enzyme induction. May require topiramate dose adjustment. | Major |
| Valproic Acid / Sodium Valproate | May decrease valproate levels slightly. Combined use increases risk of hyperammonemia, encephalopathy, and hypothermia. | Major |
| Oral Contraceptives (Ethinyl Estradiol) | Topiramate (>200 mg/day) can decrease estrogen levels, potentially reducing contraceptive efficacy. Advise use of non-hormonal backup. | Major |
| Other CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Additive sedation, dizziness, and cognitive impairment. | Moderate |
| Metformin | Increased risk of lactic acidosis due to additive effect on serum bicarbonate reduction. | Moderate |
| Lithium | Topiramate may increase lithium levels, increasing toxicity risk. Monitor lithium levels. | Moderate |
| Amitriptyline | Increased amitriptyline levels possible. Monitor for anticholinergic side effects. | Moderate |